Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant

This study is testing a drug called olutasidenib for people with certain blood cancers — acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML) — that carry a specific gene mutation called IDH1, and who have had or are about to have a stem cell transplant from a donor. **You may be eligible if...** - You are 18 or older with AML, MDS, or CMML that has the IDH1 mutation - You have had or are scheduled to have a donor stem cell transplant - You are in reasonably good health (ECOG ≤ 2 or Karnofsky ≥ 70) **You may NOT be eligible if...** - Your IDH1 mutation was not detected at the time of your diagnosis - You had a disease relapse before transplant without a detectable IDH1 mutation - You have active graft-versus-host disease after your transplant Talk to your doctor to see if this trial is right for you.